Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

Clinical trial NCT05841849 · NOT_YET_RECRUITING

Trial details

NCT number: NCT05841849
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Status: NOT_YET_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Breast Cancer Chemotherapy-induced Nausea and Vomiting

Start date: 2023-07-01
Primary completion: 2028-07-01
Enrollment: 1028

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.